Receptor-induced translocation of activated guanine-nucleotide-binding protein alpha i subunits to the cytoskeleton in myeloid differentiated human leukemia (HL-60) cells.
The regulation of the cytoskeletal localization of guanine-nucleotide-binding protein alpha i subunits by formyl peptide receptors was studied in myeloid differentiated human leukemia (HL-60) cells. Stimulation of formyl peptide receptors with N-formyl-Met-Leu-Phe (fMet-Leu-Phe) transiently increased the amount of alpha i subunits in the Triton X-100-insoluble cytoskeleton. Similar to the biphasic regulation of the actin content, fMet-Leu-Phe ( > or = 10 nM) rapidly increased the cytoskeletal alpha i content (about threefold at 30 s), which was followed by a rapid reversal to control levels. The formyl peptide receptor increased the cytoskeletal content of both alpha i subtypes, alpha i2 and alpha i3- present in HL-60 cells. In cells permeabilized with Staphylococcus aureus alpha-toxin, fMet-Leu-Phe increased binding of the stable GTP analogue, guanosine 5'-[gamma-thio]triphosphate (GTP[S]), to cytoskeletal proteins in a pertussis-toxin-sensitive manner, which was completely abolished by the F-actin-disrupting agent, cytochalasin B. Using the photoreactive GTP analogue, m-acetylanilido-GTP, the formyl peptide receptor-regulated GTP binding sites at the cytoskeleton were identified as 40-kDa proteins, the molecular size of alpha i subunits. Cytoskeleton prepared from stimulated cells did not exhibit increased GTP[S] binding, which suggests that activated alpha i subunits are translocated to the cytoskeleton. Finally, in alpha-toxin-permeabilized HL-60 cells, fMet-Leu-Phe and GTP[S] cooperatively stimulated actin polymerization. In conclusion, evidence is provided that chemoattractant receptors cause translocation of activated alpha i subunits to the cytoskeleton coincidentally with F-actin formation. The data therefore argue for a potential role of translocated alpha i subunits in the process of receptor-induced actin polymerization.
Wieland
T
T
Institut für Pharmakologie, Universitätsklinikum Essen, Germany.
Meyer zu Heringdorf
D
D
Schulze
R A
RA
Kaldenberg-Stasch
S
S
Jakobs
K H
KH
D001427:Bacterial Toxins / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D002454:Cell Differentiation; D002463:Cell Membrane Permeability; D003599:Cytoskeleton / Q000378:metabolism*; D019204:GTP-Binding Proteins / Q000378:metabolism*; D018922:HL-60 Cells; D006460:Hemolysin Proteins / Q000494:pharmacology; D006801:Humans; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology*; D037342:Pertussis Toxin; D010586:Phagocytes / Q000378:metabolism*; D011487:Protein Conformation; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic / Q000378:metabolism*; D018000:Receptors, Peptide / Q000378:metabolism*; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D001427:Bacterial Toxins; D006460:Hemolysin Proteins; D044042:Receptors, Formyl Peptide; D011971:Receptors, Immunologic; D018000:Receptors, Peptide; D010566:Virulence Factors, Bordetella; C021091:staphylococcal alpha-toxin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D037342:Pertussis Toxin; D019204:GTP-Binding Proteins